XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration and License Agreements (Tables)
12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue by Collaboration Partners

The following table summarizes the revenue by collaboration partner:

 

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

AbbVie

 

$

 

 

$

3,688

 

Amgen

 

 

3,054

 

 

 

5,739

 

Astellas

 

 

29,378

 

 

 

24,453

 

Bristol Myers Squibb

 

 

77,960

 

 

 

49,300

 

Regeneron

 

 

10,830

 

 

 

7,194

 

Moderna

 

 

16,881

 

 

 

10,840

 

Total revenue

 

$

138,103

 

 

$

101,214

 

Summary of Contract Liabilities

The following table presents changes in the Company’s total contract liabilities for the years ended in December 31, 2024 and 2023 (in thousands):

 

 

Deferred Revenue

 

 

(in thousands)

 

Balance at 12/31/2022

$

301,326

 

Additions

 

6,438

 

Revenue Recognized

 

(95,449

)

Balance at 12/31/2023

 

212,315

 

Additions

 

8,643

 

Revenue Recognized

 

(126,895

)

Balance at 12/31/2024

$

94,063